Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B viral infection.

H C Thomas1

  • 1Department of Medicine, St. Mary's Hospital Medical School, University of London, United Kingdom.

The American Journal of Medicine
|August 29, 1988
PubMed
Summary
This summary is machine-generated.

Hepatitis B virus replication can be inhibited by certain compounds, but optimal treatments are still being defined. Longer interferon therapy courses show promise for specific patient groups, improving seroconversion rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.

Journal of viral hepatitis·2016
Same author

Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency.

Metabolic brain disease·2014
Same author

Successful control of nosocomial transmission of the USA300 clone of community-acquired meticillin-resistant Staphylococcus aureus in a UK paediatric burns centre.

The Journal of hospital infection·2013
Same author

Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation.

Journal of viral hepatitis·2012
Same author

A comparison of 31P magnetic resonance spectroscopy and microbubble-enhanced ultrasound for characterizing hepatitis c-related liver disease.

Journal of viral hepatitis·2011
Same author

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*.

Journal of viral hepatitis·2011
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis B virus (HBV) replication mechanisms are understood, yet antiviral compounds are largely found empirically.
  • Current antivirals like vidarabine, acyclovir, and interferons (IFN-α, IFN-β) inhibit HBV replication, but treatment regimens are not optimized.
  • Short courses of IFN-α and IFN-β yield only transient effects on HBV replication.

Purpose of the Study:

  • To review the current understanding of hepatitis B virus replication.
  • To evaluate the efficacy of existing antiviral compounds and treatment strategies for HBV infection.
  • To explore the potential of prolonged intermittent interferon therapy in managing chronic HBV.

Main Methods:

  • Literature review of studies on HBV replication inhibitors.

Related Experiment Videos

  • Analysis of clinical trial data for vidarabine, acyclovir, and interferons (IFN-α, IFN-β).
  • Examination of treatment outcomes from short-term versus long-term intermittent interferon therapy.

    • Main Results:

    • Interferons (IFN-α, IFN-β) demonstrate inhibitory effects on HBV replication.
    • Short-term interferon therapy results in transient suppression of HBV replication.
    • Longer courses of intermittent therapy achieved up to 50% seroconversion rates in Western European HBV carriers.
    • Patients with adult-acquired HBV infection, often deficient in IFN-α, show the best response to prolonged intermittent therapy.

    Conclusions:

    • Optimal treatment regimens for hepatitis B virus infection require further definition.
    • Protracted intermittent interferon therapy is a promising strategy for specific HBV-infected patient populations.
    • Targeting interferon-deficient patients with prolonged therapy may enhance treatment efficacy and seroconversion rates.